{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:06:54Z","timestamp":1790662014947,"version":"4.1.0"},"reference-count":262,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.autrev.2022.103143","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T10:29:50Z","timestamp":1657880990000},"page":"103143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Seronegative autoimmune diseases: A challenging diagnosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Marco Vincenzo","family":"Lenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Melazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Ilaria","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Chiovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino Roberto","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2022.103143_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0015","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103143_bb0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevImmunol.2019031798","article-title":"Prevalence of autoimmune diseases and its challenges in diagnosis","volume":"39","author":"Chauhan","year":"2019","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0030","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2014.5","article-title":"Gene-environment interaction in autoimmune disease","volume":"16","author":"Ellis","year":"2014","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.autrev.2008.07.032","article-title":"Recent advances in diagnostic technologies for autoimmune diseases","volume":"8","author":"Plebani","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0040","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2022.103143_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.548469","article-title":"Autoantibodies targeting intracellular and extracellular proteins in autoimmunity","volume":"12","author":"Burbelo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0050","series-title":"Warm Autoimmune Hemolytic Anemia","first-page":"647","volume":"381","author":"Brodsky","year":"2019"},{"key":"10.1016\/j.autrev.2022.103143_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2017.06.010","article-title":"Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases","author":"Di Sabatino","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0060","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(09)60254-3","article-title":"Coeliac disease","volume":"373","author":"Di Sabatino","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103143_bb0065","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.dld.2021.10.001","article-title":"Time course and risk factors of evolution from potential to overt autoimmune gastritis","volume":"54","author":"Lenti","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/imr.12813","article-title":"The five dimensions of B cell tolerance","volume":"292","author":"Platt","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0075","series-title":"Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders","volume":"13","author":"Kuwana","year":"2021"},{"key":"10.1016\/j.autrev.2022.103143_bb0080","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103143_bb0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/iid3.401","article-title":"Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity","volume":"9","author":"Shang","year":"2021","journal-title":"Immunity, Inflamm Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0090","article-title":"Antibody-negative autoimmune encephalitis as a complication of long-term immune-suppression for liver transplantation","volume":"13","author":"Spindel","year":"2020","journal-title":"BMJ Case Reports CP"},{"key":"10.1016\/j.autrev.2022.103143_bb0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000510701","article-title":"Disappearance of anti-thyroid autoantibodies following thymectomy in patients with Myasthenia Gravis","volume":"10","author":"Rotondo Dottore","year":"2021","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.autrev.2022.103143_bb0100","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00010","article-title":"Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens","volume":"139","author":"Chiovato","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0105","first-page":"1","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes?","volume":"8","author":"Fulop","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-cellbio-011620-034148","article-title":"B Cell immunosenescence","volume":"36","author":"Frasca","year":"2020","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.autrev.2022.103143_bb0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.dld.2018.03.010","article-title":"Frailty and the gut","volume":"50","author":"Di Sabatino","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0120","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.dld.2020.04.015","article-title":"Seronegative autoimmune atrophic gastritis is more common in elderly patients","volume":"52","author":"Conti","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.gastro.2020.08.060","article-title":"AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review","volume":"160","author":"Ananthakrishnan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2022.103143_bb0130","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","article-title":"Rheumatoid arthritis in the elderly: Characteristics and treatment considerations","volume":"19","author":"Serhal","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1741-7015-11-94","article-title":"Age-related autoimmunity","volume":"11","author":"Vadasz","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.anai.2019.07.014","article-title":"Autoimmunity in common variable immunodeficiency","volume":"123","author":"Agarwal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0145","doi-asserted-by":"crossref","first-page":"648","DOI":"10.14309\/ajg.0000000000000140","article-title":"A high prevalence of gastrointestinal manifestations in common variable immunodeficiency","volume":"114","author":"Pikkarainen","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-020-0187-8","article-title":"Autoimmune gastritis","volume":"6","author":"Lenti","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2022.103143_bb0155","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archinte.1996.00040041097008","article-title":"Prevalence of undiagnosed pernicious anemia in the elderly","volume":"156","author":"Carmel","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2018.08.011","article-title":"The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective","volume":"18","author":"Massironi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cgh.2012.02.018","article-title":"Common features of patients with autoimmune atrophic gastritis","volume":"10","author":"Miceli","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/apt.15317","article-title":"Determinants of diagnostic delay in autoimmune atrophic gastritis","volume":"50","author":"Lenti","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0175","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11739-018-1823-0","article-title":"Infertility and recurrent miscarriage in a patient with autoimmune atrophic gastritis","volume":"13","author":"Lenti","year":"2018","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCG.0000000000000101","article-title":"A laboratory score in the diagnosis of autoimmune atrophic gastritis: a prospective study","volume":"49","author":"Miceli","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0185","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/apt.15540","article-title":"Natural history of autoimmune atrophic gastritis: a prospective, single centre, long-term experience","volume":"50","author":"Miceli","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0190","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.autrev.2022.103143_bb0195","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12016-010-8218-y","article-title":"Cutting edge issues in autoimmune gastritis","volume":"42","author":"Toh","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0200","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/ajg.2009.231","article-title":"Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency","volume":"104","author":"Lahner","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0205","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1055-9965.EPI-12-1343","article-title":"Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany","volume":"22","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.autrev.2022.103143_bb0210","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.autrev.2010.08.006","article-title":"Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases","volume":"10","author":"Tozzoli","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0215","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.dld.2020.04.015","article-title":"Seronegative autoimmune atrophic gastritis is more common in elderly patients","volume":"52","author":"Conti","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10238-004-0027-2","article-title":"Common variable immunodeficiency: a review","volume":"3","author":"Di Renzo","year":"2004","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0225","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.14248","article-title":"Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis","volume":"46","author":"Zagari","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0230","doi-asserted-by":"crossref","first-page":"866167","DOI":"10.3389\/fimmu.2022.866167","article-title":"Increase of deep intraepithelial lymphocytes in the oxyntic mucosa of patients with potential and overt autoimmune gastritis","volume":"13","author":"Lenti","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.autrev.2022.103143_bb0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MPG.0000000000002497","article-title":"European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing celiac disease 2020","volume":"70","author":"Husby","year":"2020","journal-title":"Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.autrev.2022.103143_bb0240","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.gastro.2018.12.010","article-title":"AGA clinical practice update on diagnosis and monitoring of celiac disease: changing utility of serology and histologic measures: expert review","volume":"156","author":"Husby","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2022.103143_bb0245","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/2050640619844125","article-title":"European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders","volume":"7","author":"Al-Toma","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2022.103143_bb0250","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac disease: a comprehensive current review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0255","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ajg.2013.45","article-title":"Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma","volume":"108","author":"DeGaetani","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0260","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.dld.2016.05.024","article-title":"Seronegative celiac disease: shedding light on an obscure clinical entity","volume":"48","author":"Volta","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.dld.2019.11.011","article-title":"Prevalence and diagnostic outcomes of children with duodenal lesions and negative celiac serology","volume":"52","author":"Gustafsson","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0270","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/apt.16599","article-title":"Clinical classification and long-term outcomes of seronegative coeliac disease: a 20-year multicentre follow-up study","volume":"10","author":"Schiepatti","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0275","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0300-2977(98)00050-3","article-title":"SAT and serology in adult celiacs, seronegative celiac disease seems a reality","volume":"53","author":"Rostami","year":"1998","journal-title":"Neth J Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0280","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1572-0241.1999.983_f.x","article-title":"Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice","volume":"94","author":"Rostami","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/003655200750024362","article-title":"Reliance on serum endomysial antibody testing underestimates the true prevalence of coeliac disease by one fifth","volume":"35","author":"Dickey","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0290","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2036.2010.04337.x","article-title":"Antibiodies against deamidated gliadin peptides identify adult coeliac disease patients negative for antibodies against endomysium and tissue transglutaminase","volume":"32","author":"Dahle","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0295","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1023\/B:DDAS.0000026296.02308.00","article-title":"Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy","volume":"49","author":"Abrams","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2022.103143_bb0300","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/gut.2005.071514","article-title":"Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits","volume":"55","author":"Salmi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2022.103143_bb0305","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2036.2011.04938.x","article-title":"Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice","volume":"35","author":"Pallav","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0310","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/gutjnl-2016-312271","article-title":"The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000\u20132015)","volume":"66","author":"Aziz","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2022.103143_bb0315","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/MEG.0000000000000836","article-title":"Short article: mortality and differential diagnoses of villous atrophy without coeliac antibodies","volume":"29","author":"Schiepatti","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0320","doi-asserted-by":"crossref","first-page":"492","DOI":"10.14309\/ajg.0000000000000575","article-title":"Management of small bowel villous atrophy in patients seronegative for celiac disease","volume":"115","author":"Jansson-Knodell","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0325","first-page":"1652052","article-title":"Seronegative coeliac disease in children: a case report and review of the literature case","volume":"2017","author":"Kolimarala","year":"2017","journal-title":"Rep Pediatr"},{"key":"10.1016\/j.autrev.2022.103143_bb0330","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1067\/mge.2000.104977","article-title":"All that scallops is not celiac disease","volume":"51","author":"Shah","year":"2000","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.autrev.2022.103143_bb0335","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bpg.2012.11.013","article-title":"Diarrhoea due to small bowel diseases","volume":"26","author":"Murray","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-230X-9-19","article-title":"Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers","volume":"9","author":"Ludvigsson","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0345","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/his.12522","article-title":"The biopsy pathology of non-coeliac enteropathy","volume":"66","author":"Greenson","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.autrev.2022.103143_bb0350","series-title":"A Comprehensive Review of Celiac Disease\/Gluten-Sensitive Enteropathies Clinical Reviews in Allergy & Immunology","first-page":"226","volume":"57","author":"McAllister","year":"2019"},{"key":"10.1016\/j.autrev.2022.103143_bb0355","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1053\/j.gastro.2020.08.061","article-title":"AGA clinical practice update on the evaluation and management of seronegative enteropathies: expert review","volume":"160","author":"Leonard","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2022.103143_bb0360","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOG.0000000000000436","article-title":"Seronegative coeliac disease: clearing the diagnostic dilemma","volume":"34","author":"Schiepatti","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0365","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MEG.0000000000001340","article-title":"Overview in the clinical management of patients with seronegative villous atrophy","volume":"31","author":"Schiepatti","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00042737-200501000-00017","article-title":"Antiendomysial and antihuman recombinant tissue transglutaminase antibiodies in the diagnosis of celiac disease: a biopsy proven European multicenter study","volume":"17","author":"Collin","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0375","doi-asserted-by":"crossref","first-page":"94","DOI":"10.15171\/mejdd.2017.57","article-title":"Clinicopathological study of seronegative celiac disease in adults in Pakistan: a pilot study","volume":"9","author":"Farina","year":"2017","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0380","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gut.42.3.362","article-title":"Prevalence and clinical features of selective immunoglobulin A deficiency in celiac disease: an Italian multicenter study","volume":"42","author":"Cataldo","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2022.103143_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1309\/AJCPEIILH2C0WFYE","article-title":"The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study","volume":"138","author":"Biagi","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.autrev.2022.103143_bb0390","doi-asserted-by":"crossref","first-page":"7486","DOI":"10.3390\/nu7095350","article-title":"Seronegative Celiac Disease and immunoglobulin deficiency: where to look in the submerged iceberg?","volume":"7","author":"Giorgio","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.autrev.2022.103143_bb0395","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000630","article-title":"Enteropathies with villous atrophy but negative coeliac serology in adults: current issues","volume":"8","author":"Schiepatti","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0400","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103143_bb0405","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/nu10050602","article-title":"Dermatitis herpetiformis: a common extraintestinal manifestation of celiac disease","volume":"1","author":"Reunala","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.autrev.2022.103143_bb0410","first-page":"836","article-title":"IgA anti-epidermal transglutaminase autoantibodies: a sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients","volume":"27","author":"Borroni","year":"2013","journal-title":"JEADV"},{"key":"10.1016\/j.autrev.2022.103143_bb0415","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2006.095299","article-title":"Spectrum of gluten-sensitive enteropathy in first-degree relatives of patients with celiac disease: clinical relevance of lymphocytic enteritis","volume":"55","author":"Esteve","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2022.103143_bb0420","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1590\/s0004-2803.202100000-39","article-title":"Seronegative celiac disease in Brazilian patients: a series of cases","volume":"58","author":"Kotze","year":"2021","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0425","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/MEG.0000000000001726","article-title":"Clinical phenotype and mortality in patients with idiopathic small bowel villous atrophy: a dual-center international study","volume":"32","author":"Schiepatti","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0430","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3390\/cancers13102289","article-title":"Serum markers of refractoriness and enteropathy-associated T-Cell Lymphoma in Coeliac disease","volume":"13","author":"Lenti","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.autrev.2022.103143_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2017-000159","article-title":"Clinical and genetic profile of patients with seronegative celiac disease: the natural history and response to gluten-free diet","volume":"4","author":"Dore","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0440","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/00365521.2019.1608466","article-title":"Genetic and flow cytometry analysis of seronegative celiac disease: a cohort study","volume":"54","author":"R\u00edos Le\u00f3n","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0445","first-page":"110","article-title":"Seronegative celiac disease: where is the specific setting?","volume":"8","author":"Ierardi","year":"2015","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"10.1016\/j.autrev.2022.103143_bb0450","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MPG.0b013e3181677067","article-title":"Immunoglobulin A anti-tissue transglutaminase antibody deposits in the small intestinal mucosa of children with no villous atrophy","volume":"47","author":"Tosco","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.autrev.2022.103143_bb0455","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/00365520510023422","article-title":"Small bowel mucosal transglutaminase 2-specific IgA deposists in coeliac disease without villous atrophy: a prospective and randomized clinical study","volume":"40","author":"Kaukinen","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0460","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apt.15663","article-title":"Gamma delta+ intraepithelial lymphocytes and celiac lymphogram in a diagnostic approach to celiac disease in patients with seronegative villous atrophy","volume":"51","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0465","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/gutjnl-2011-300327","article-title":"Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis","volume":"61","author":"Heyman","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2022.103143_bb0470","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apm.12800","article-title":"Serum intestinal fatty acid-binding protein in the noninvasive diagnosis of celiac disease","volume":"126","author":"Oldenburger","year":"2018","journal-title":"APMIS"},{"key":"10.1016\/j.autrev.2022.103143_bb0475","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0480","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study","volume":"43","author":"Werner","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0485","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103143_bb0490","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s10620-011-2017-z","article-title":"Autoantibody-negative autoimmune hepatitis","volume":"57","author":"Czaja","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2022.103143_bb0495","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00508-021-01907-x","article-title":"Seronegative autoimmune hepatitis in children: a real diagnostic challenge","volume":"134","author":"Khedr","year":"2021","journal-title":"Wien Klin Wochenschr"},{"issue":"113","key":"10.1016\/j.autrev.2022.103143_bb0500","first-page":"185","article-title":"Pathology of autoimmune hepatitis","author":"Covelli","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.autrev.2022.103143_bb0505","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00535-005-1711-z","article-title":"Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?","volume":"40","author":"Yatsuji","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0510","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Acute Liver Failure Study Group. Autoimmune acute liver failure: proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103143_bb0515","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0520","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103143_bb0525","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s13317-013-0046-7","article-title":"Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis","volume":"4","author":"Himoto","year":"2013","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.autrev.2022.103143_bb0530","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80096-8","article-title":"Behavior and significance of autoantibodies in type 1 autoimmune hepatitis","volume":"30","author":"Czaja","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0535","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103143_bb0540","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-010-1501-1","article-title":"Performance parameters of the conventional serological markers for autoimmune hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2022.103143_bb0545","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0550","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","article-title":"Antibodies to soluble liver antigen\/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0555","first-page":"2197","article-title":"Genetic distinctions between types 1 and 2 autoimmune hepatitis","volume":"92","author":"Czaja","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0065-2423(05)40004-9","article-title":"Autoantibodies in autoimmune liver disease","volume":"40","author":"Czaja","year":"2005","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.autrev.2022.103143_bb0565","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/MCG.0b013e3181587d18","article-title":"Frequency, behaviour, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis","volume":"42","author":"Montano-Loza","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0570","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/MEG.0000000000000975","article-title":"Autoimmune acute liver failure and seronegative autoimmune liver disease in children: Are they different from classical disease?","volume":"29","author":"Jain","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0575","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep4.1044","article-title":"Toward solving the etiological mystery of primary biliary cholangitis","volume":"1","author":"Tanakaa","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.autrev.2022.103143_bb0580","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"56","key":"10.1016\/j.autrev.2022.103143_bb0585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/cclm-2017-0249","article-title":"The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature","volume":"2017","author":"De Liso","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0590","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2022.103143_bb0595","first-page":"585","article-title":"Detection of anti-kelch-like 12 and anti-hexokinase 1 antibodies in primary biliary cholangitis patients in China","volume":"113","author":"Liu","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.autrev.2022.103143_bb0600","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1089-3261(03)00101-6","article-title":"Primary biliary cirrhosis- presentation and diagnosis","volume":"7","author":"Leuschner","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0605","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jhep.2007.05.011","article-title":"The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study","volume":"47","author":"Bernal","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0610","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2022.103143_bb0615","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0620","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2022.103143_bb0625","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0630","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0635","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","article-title":"Serum autoantibodies in patients with primary sclerosing cholangitis","volume":"32","author":"Angulo","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0640","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/gut.33.5.657","article-title":"Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"33","author":"Seibold","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2022.103143_bb0645","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis","volume":"14","author":"Hov","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2022.103143_bb0650","first-page":"439","article-title":"Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC and multivariate regression analysis","volume":"9","author":"Terjung","year":"2004","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.autrev.2022.103143_bb0655","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1440-1746.1994.tb01214.x","article-title":"Anti-neutrophil cytoplasmatic antibody: a prognostic indicator in p-ANCA in primary biliary cholangitis","volume":"9","author":"Pokorny","year":"1994","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0660","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1056\/NEJMra021194","article-title":"Thyroiditis","volume":"348","author":"Pearce","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0665","doi-asserted-by":"crossref","first-page":"750380","DOI":"10.3389\/fphar.2021.750380","article-title":"Precision medicine in autoimmune thyroiditis and hypothyroidism","volume":"12","author":"Ferrari","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2022.103143_bb0670","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/er.2006-0044","article-title":"Role of chemokines in endocrine autoimmune diseases","volume":"28","author":"Rotondi","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0675","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/BF03347031","article-title":"Thyroid ultrasound as a predicator of thyroid disease","volume":"26","author":"Vitti","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2022.103143_bb0680","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/BF03343925","article-title":"Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dysfunction in apparently healthy subjects","volume":"24","author":"Rago","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2022.103143_bb0685","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1530\/eje.1.02255","article-title":"The association between hypoechogenicity or irregular echo pattern at thyroid ultrasonography and thyroid function in the general population","volume":"155","author":"Vejbjerg","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2022.103143_bb0690","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40618-014-0083-8","article-title":"Serum-negative autoimmune thyroiditis: what\u2019s in a name?","volume":"37","author":"Rotondi","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2022.103143_bb0695","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/jc.2010-2515","article-title":"Thyroid and obesity: not a one-way interaction","volume":"96","author":"Rotondi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2022.103143_bb0700","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1210\/jc.2008-0823","article-title":"Thyroid function and structure are affected in childhood obesity","volume":"93","author":"Radetti","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.autrev.2022.103143_bb0705","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1530\/EJE-10-0288","article-title":"A hypoechoic pattern of the thyroid at ultrasound does not indicate autoimmune thyroid diseases in patients with morbid obesity","volume":"163","author":"Rotondi","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2022.103143_bb0710","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-108-1-26","article-title":"Seronegative Hashimoto thyroiditis with thyroid autoantibody production localized to the thyroid","volume":"108","author":"Baker","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0715","first-page":"174","article-title":"Subclassification of seronegative type 1 diabetic subjects with HLA-DQ genotypes","volume":"43","author":"Zhang","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.autrev.2022.103143_bb0720","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02207661","article-title":"Anti-thyroid microsomal antibody in synovial fluid as a revealing feature of seronegative autoimmune thyroiditis","volume":"10","author":"Punzi","year":"1991","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0725","first-page":"173","article-title":"Seronegative hashitoxicosis in patient with rheumatoid arthritis","volume":"15","author":"Spina","year":"1990","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.autrev.2022.103143_bb0730","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-14-0147","article-title":"Serum negative autoimmune thyroiditis displays a milder clinical picture compared with classic Hashimoto\u2019s thyroiditis","volume":"171","author":"Rotondi","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.autrev.2022.103143_bb0735","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s40618-020-01249-x","article-title":"Compared with classic Hashimoto\u2019s thyroiditis, chronic autoimmune serum-negative thyroiditis requires a lower substitution dose of L-thyroxine to correct hypothyroidism","volume":"43","author":"Croce","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.autrev.2022.103143_bb0740","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2022.103143_bb0745","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0750","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2022.103143_bb0755","first-page":"175","article-title":"1958 Revision of diagnostic criteria for rheumatoid arthritis","volume":"9","author":"Ropes","year":"1958","journal-title":"Bull Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0760","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103143_bb0765","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0770","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fmed.2018.00339","article-title":"The clinical value of autoantibodies in rheumatoid arthritis","volume":"5","author":"Bugatti","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2022.103143_bb0775","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001228","article-title":"Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis","volume":"7","author":"Catrina","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2022.103143_bb0780","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","article-title":"Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014","volume":"79","author":"Myasoedova","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0785","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1136\/annrheumdis-2020-217609","article-title":"Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population","volume":"81","author":"Matthijssen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2022.103143_bb0790","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard.2010.130625","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0795","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1093\/rheumatology\/keaa623","article-title":"Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study","volume":"60","author":"Paalanen","year":"2021","journal-title":"Heumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103143_bb0800","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.semarthrit.2016.07.004","article-title":"Self-limiting arthritis among patients fulfilling the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis in a very early arthritis cohort","volume":"46","author":"Norli","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103143_bb0805","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.jtauto.2022.100142","article-title":"Impact of autoimmune serology test results on RA classification and diagnosis","volume":"5","author":"Van Hoovels","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2022.103143_bb0810","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2017-212365","article-title":"Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR\/EULAR classification of rheumatoid arthritis","volume":"77","author":"Van Hoovels","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0815","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2017-211782","article-title":"Anticitrullinated protein\/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants","volume":"77","author":"R\u00f6nnelid","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0820","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-020-02191-2","article-title":"Presence of autoantibodies in \u201cseronegative\u201d rheumatoid arthritis associates with classical risk factors and high disease activity","volume":"22","author":"Reed","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb0825","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.12829","article-title":"Autoantibodies and B Cells: the ABC of rheumatoid arthritis pathophysiology","volume":"294","author":"Volkov","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0830","doi-asserted-by":"crossref","first-page":"12386","DOI":"10.3390\/ijms222212386","article-title":"The genetic, environmental, and immunopathological complexity of autoantibody-negative rheumatoid arthritis","volume":"22","author":"De Stefano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2022.103143_bb0835","doi-asserted-by":"crossref","first-page":"101478","DOI":"10.1016\/j.berh.2019.101478","article-title":"Established rheumatoid arthritis. The pathogenic aspects","volume":"33","author":"Bugatti","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0840","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.41184","article-title":"B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure","volume":"72","author":"Rivellese","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2022.103143_bb0850","doi-asserted-by":"crossref","first-page":"102531","DOI":"10.1016\/j.autrev.2020.102531","article-title":"Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014","volume":"19","author":"Scherlinger","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0855","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2022.103143_bb0860","first-page":"35","article-title":"ACR-EULAR Classification Criteria for primary Sj\u00f6gren\u2019s Syndrome: a consensus and data-driven methodology involving three international patient Cohorts","volume":"69","author":"Shiboski","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ) 2017"},{"key":"10.1016\/j.autrev.2022.103143_bb0865","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/38.3.245","article-title":"Primary Sj\u00f6gren\u2019s syndrome in the North East of England: a long-term follow-up study","volume":"38","author":"Davidson","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2022.103143_bb0870","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0875","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clim.2017.03.017","article-title":"Autoantibodies, detection methods and panels for diagnosis of Sj\u00f6gren\u2019s syndrome","volume":"182","author":"Shen","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0880","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sj\u00f6gren\u2019s Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2022.103143_bb0885","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.clim.2012.09.013","article-title":"Novel autoantibodies in Sjogren\u2019s syndrome","volume":"145","author":"Shen","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb0890","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.autrev.2015.07.002","article-title":"Anti-SSA\/SSB-negative Sj\u00f6gren\u2019s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution","volume":"14","author":"Quartuccio","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb0895","first-page":"S102","article-title":"How immunological profile drives clinical phenotype of primary Sj\u00f6gren\u2019s syndrome at diagnosis: analysis of 10,500 patients (Sj\u00f6gren Big Data Project)","volume":"36","author":"Brito-Zer\u00f3n","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0900","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10067-020-05154-9","article-title":"Clinical and serological characteristics of seronegative primary Sj\u00f6gren\u2019s syndrome: a comparative study","volume":"40","author":"Yazisiz","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0905","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/acn3.51053","article-title":"Immune-mediated axonal dysfunction in seropositive and seronegative primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Tani","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb0910","first-page":"285","article-title":"The anticardiolipin syndrome","volume":"3","author":"Hughes","year":"1985","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0915","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103143_bb0920","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb0925","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2019.221945","article-title":"Seronegative antiphospholipid syndrome: refining the value of \u201cnon-criteria\u201d antibodies for diagnosis and clinical management","volume":"105","author":"Pignatelli","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2022.103143_bb0930","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome:\u2019extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0935","doi-asserted-by":"crossref","first-page":"389601","DOI":"10.1155\/2014\/389601","article-title":"The Mosaic of \u201cSeronegative\u201d antiphospholipid syndrome","volume":"2014","author":"Conti","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2022.103143_bb0940","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/0961203309106920","article-title":"Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome","volume":"18","author":"Sanmarco","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103143_bb0945","first-page":"1369","article-title":"Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases","volume":"23","author":"Berard","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb0950","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0037-1615751","article-title":"Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses","volume":"85","author":"Sanmarco","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103143_bb0955","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1160\/TH06-10-0604","article-title":"Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies","volume":"97","author":"Sanmarco","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103143_bb0960","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/s-0037-1614001","article-title":"Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study \u2013 NOHA","volume":"84","author":"Gris","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103143_bb0965","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.revmed.2018.11.013","volume":"40","author":"Billoir","year":"2019","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2022.103143_bb0970","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib5020016","article-title":"The significance of Anti-Beta-2- Glycoprotein I antibodies in antiphospholipid syndrome","volume":"5","author":"Brusch","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.autrev.2022.103143_bb0975","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/art.38131","article-title":"Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome","volume":"65","author":"Murthy","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103143_bb0980","doi-asserted-by":"crossref","first-page":"704395","DOI":"10.1155\/2014\/704395","article-title":"Isolated IgA anti- beta2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome","volume":"2014","author":"Ruiz-Garcia","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2022.103143_bb0985","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cca.2019.04.065","article-title":"Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome","volume":"495","author":"Zhang","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2022.103143_bb0990","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/0961203310397082","article-title":"\u2018Non-criteria\u2019 aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010","volume":"20","author":"Bertolaccini","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103143_bb0995","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.fertnstert.2009.01.166","article-title":"Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses","volume":"93","author":"Jaslow","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.autrev.2022.103143_bb1000","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cei.13633","article-title":"Anti-vimentin\/cardiolipin IgA in the anti-phospholipid syndrome: A new tool for \u2018seronegative\u2019 diagnosis","volume":"205","author":"Capozzi","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2022.103143_bb1005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3899\/jrheum.170044","article-title":"Closing the serological gap in the antiphospholipid syndrome: the value of \u201cNon-criteria\u201d antiphospholipid antibodies","volume":"44","author":"Zohoury","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2022.103143_bb1010","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0002-9440(10)63479-7","article-title":"Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay","volume":"163","author":"Rand","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2022.103143_bb1015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/jth.13699","article-title":"Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes","volume":"15","author":"Wolgast","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2022.103143_bb1020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/ard.2010.145177","article-title":"Risk Scale for the diagnosis of antiphospholipid syndrome","volume":"70","author":"Sciascia","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2022.103143_bb1025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103143_bb1030","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/0961203314537361","article-title":"Antiphospholipid scoring: significance in diagnosis and prognosis","volume":"23","author":"Oku","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2022.103143_bb1035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-021-02702-9","article-title":"The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study","volume":"24","author":"Da Rosa","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2022.103143_bb1040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103143_bb1045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/brain\/91.3.481","article-title":"\u201cLimbic encephalitis\u201d and its association with carcinoma","volume":"91","author":"Corsellis","year":"1968","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2022.103143_bb1050","first-page":"930","article-title":"Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations","volume":"71","author":"Graus","year":"2008","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.autrev.2022.103143_bb1055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb1060","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.autrev.2022.103143_bb1065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.24200","article-title":"Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms","volume":"76","author":"Irani","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1070","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2022.103143_bb1075","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103143_bb1080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1085","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.24293","article-title":"Cellular plasticity induced by anti-\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies","volume":"77","author":"Peng","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1095","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01394","article-title":"In vivo mechanisms of antibody-mediated neurological disorders: animal models and potential implications","volume":"10","author":"Giannoccaro","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1105","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.410440620","article-title":"Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy","volume":"44","author":"Molinuevo","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10072-017-3031-5","article-title":"Diagnostics of paraneoplastic neurological syndromes","volume":"38","author":"Zoccarato","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103143_bb1120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10072-017-3032-4","article-title":"Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens","volume":"38","author":"Zuliani","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103143_bb1125","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000404","article-title":"Improving the antibody-based evaluation of autoimmune encephalitis","volume":"4","author":"McCracken","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.autrev.2022.103143_bb1130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/ene.14139","article-title":"Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study","volume":"27","author":"Gastaldi","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1145","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/ene.13661","article-title":"Syndrome and outcome of antibody-negative limbic encephalitis","volume":"25","author":"Graus","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1150","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2022.103143_bb1155","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103143_bb1160","doi-asserted-by":"crossref","first-page":"605902","DOI":"10.3389\/fneur.2020.605902","article-title":"Controversies in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2022.103143_bb1170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuroscience.2020.03.009","article-title":"Antibodies and receptors: from neuromuscular junction to central nervous system","volume":"439","author":"Vincent","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.autrev.2022.103143_bb1175","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2022.103143_bb1180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2022.103143_bb1185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fnmol.2020.00159","article-title":"Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment","volume":"13","author":"Cao","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.autrev.2022.103143_bb1190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.1179220","article-title":"Myasthenia gravis: passive transfer from man to mouse","volume":"190","author":"Toyka","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.autrev.2022.103143_bb1195","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis: II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies*","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2022.103143_bb1200","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103143_bb1210","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2022.103143_bb1215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2022.103143_bb1220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody\u2013positive myasthenia gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2022.103143_bb1225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103143_bb1235","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative Myasthenia Gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1240","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103143_bb1245","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.47.6.1552","article-title":"A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis","volume":"47","author":"Beeson","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103143_bb1250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-1656(99)00099-1","article-title":"Protection of immunoreactivity of dry immobilized proteins on microtitration plates in ELISA: application for detection of autoantibodies in Myasthenia gravis","volume":"72","author":"Nguyen","year":"1999","journal-title":"J Biotechnol"},{"key":"10.1016\/j.autrev.2022.103143_bb1255","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3389\/fneur.2019.01385","article-title":"Autoantibody diagnostics in neuroimmunology: experience from the 2018 Italian Neuroimmunology Association External Quality Assessment Program","volume":"10","author":"Gastaldi","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1260","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u201cseronegative\u201d myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2022.103143_bb1265","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1270","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2022.103143_bb1275","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mus.27103","article-title":"Autoantibodies in Japanese patients with ocular myasthenia gravis","volume":"63","author":"Nagaishi","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2022.103143_bb1280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13019-016-0533-9","article-title":"The clinical features, diagnosis and management of recurrent thymoma","volume":"11","author":"Luo","year":"2016","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.autrev.2022.103143_bb1285","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in \u2018seronegative\u2019 myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1290","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103143_bb1295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0404.2006.00609.x","article-title":"Myasthenia gravis: disease severity and prognosis","volume":"113","author":"Romi","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2022.103143_bb1300","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2022.103143_bb1305","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103143_bb1310","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold","year":"2021","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:06Z","timestamp":1761600426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":262,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1568997222001136"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103143","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seronegative autoimmune diseases: A challenging diagnosis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103143"}}